Bristol Myers prunes pipeline amid new round of cost cuts
Bristol Myers Squibb is ending work on a handful of assets, including an immunology medication that was in two Phase 3 trials.
The pipeline cuts …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
